On Jun. 1, 2020, Anixa Biosciences and OntoChem announced they had synthesized four potential Covid-19 compounds that will advance to biological assay testing. The initial phase of this program was designed to screen approximately 1.2 billion chemical compounds, utilizing in silico methods, against two specific enzymes of SARS-CoV-2.